GTBP GT Biopharma Corp: יחס שווי שוק לערך בספרים

GT Biopharma, Inc. (GTBP) strives for leadership in myeloid leukemia therapy by activating the patient's NK cells. Business protection is based on patents and clinical survival rates, while the binary risks of a narrow pipeline are minimized through partnerships. The current price-to-book multiple trend demonstrates asset valuation volatility, while 2.81 reflects the metric's baseline level.

The mvsbcap_co ratio determines the market value premium over the company's real net assets. By analyzing the current market-to-book value ratio, an investor assesses the extent to which the price is inflated relative to capital. This metric reveals the speculative gap between the exchange rate and the book value. For GT Biopharma, Inc. (GTBP), such a premium reflects market expectations for the commercial success of the TriKE platform. The potential of the blood cancer therapy is priced into the shares in an anticipatory manner.